KBI-BIOPHARMA
6.7.2022 13:47:10 CEST | Business Wire | Press release
KBI Biopharma SA (KBI) and Selexis SA, both JSR Life Sciences companies, held a joint ribbon-cutting ceremony yesterday at their new state-of-the-art facility in Geneva, Switzerland. Designed to directly serve the increased demand for biopharmaceutical drug development and manufacturing in Europe, the facility will support an integrated, end-to-end process of Selexis’ cell line development (CLD) services along with KBI’s contract development and manufacturing services for industry clients throughout the immediate region and beyond.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220706005082/en/
As demand for innovative biologics and effective biosimilars to treat cancer, infectious diseases, and autoimmune diseases continue to rise in Europe and around the world, developing and manufacturing these and other therapeutics, remains complex and time-consuming. By co-locating in one facility, KBI and Selexis will deliver trusted, streamlined, and cost-effective solutions to help clients confidently advance their investigational therapies.
“The opening of our Geneva facility last month was a major milestone for KBI and Selexis, and we are excited to come together today and commemorate this great achievement,” said Mark W. Womack, CEO of KBI and Selexis. “KBI and Selexis have a long history of success together. Our collaboration has accelerated more than 60 drug development programs in Europe and worldwide. Integrating Selexis’ world-renowned CLD services with KBI’s process development innovation and excellence, as well as clinical and commercial manufacturing experience provides our clients with seamless, cost-effective, and reliable development and manufacturing for their products. Our aim has always been to help our clients bring novel and effective therapies to the clinic and the market faster. This facility will help advance that mission.”
The ~94,000 square-foot facility will house new laboratories to support Selexis’ unique technical cell line workflows and KBI’s process development and cGMP manufacturing and quality control with a suite of analytical testing laboratories and cGMP single-use manufacturing trains. The expansion will generate over 300 positions in development, operations, and quality assurance. The ribbon-cutting, held on July 5, was attended by the following:
- Luca Bolliger, VP of the Swiss Biotech Association and President of the Swiss Biotech Success Stories Jury
- Mario Rodriguez, Mayor of Plan-les-Ouates
- Fabienne Fischer, State Councilor - Member of the Geneva government, Head of the economy and employment department (DEE)
“I am delighted with the development of KBI and Selexis' activities in Geneva, which contributes to the development of the life sciences sector in Geneva and reinforces our local ecosystem,” said Councilor Fischer. “It also demonstrates the potential and attractiveness of our region.”
About KBI Biopharma, Inc.
KBI Biopharma SA is a wholly-owned subsidiary of KBI Biopharma, Inc., and a JSR Life Sciences company. KBI Biopharma is a leading global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. With each of its 500+ client partners, KBI works closely to personalize and accelerate drug development programs. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps clients advance drug candidates into the clinic and beyond. KBI serves its global clients with multiple locations in Europe and the USA. www.kbibiopharma.com
About Selexis SA
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global client partners have utilized Selexis technologies to advance more than 160 drug candidates in preclinical and clinical development and manufacture ten commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220706005082/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Investment Is Outpacing Organizations' Ability to Realize Value, New HTEC Research Finds15.9.2026 14:47:00 CEST | Press release
Global survey of 1,500 C-level executives shows value realization sits at the intersection of investment, organizational readiness, governance and ability to measure desired outcomes and warns of a widening gap that is bottlenecking returns on AI. HTEC, a global product engineering and AI transformation company, today released preview findings from its AI Value Realization Report 2026, based on a survey of 1,500 C-level executives across the US, UK, Germany, and the UAE. The research reveals that AI investment is accelerating faster than organizations' ability to absorb it — creating a growing bottleneck between what companies are spending on AI and the value they are actually able to realize from it. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915718678/en/ HTEC, a global product engineering and AI transformation company, today released preview findings from its AI Value Realization Report 2026, based on a survey of 1
Telness Tech Becomes Valdyr, Making Seamless OS the AI-Native Execution Layer for Telecom Operators15.9.2026 14:30:00 CEST | Press release
The company behind Seamless OS, now serving Telia and Truecaller, takes a new name as it turns to making large established operators AI-native. Valdyr positions Seamless OS as the AI-native execution layer for telecom operators: the layer on which commercial decisions are carried out, rather than a system of record that reports on them. Offers, subscriptions, billing, provisioning, customer journeys and integrations run in one place, telecom processes are built as automated workflows instead of custom development, and AI is applied to commercial and customer-facing operations inside the platform rather than sold as a separate product. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915818094/en/ Telness Tech is rebranding and becoming Valdyr The platform supports operators across the United States, Europe and beyond. Recent additions include Telia, the Nordic incumbent operator, and Truecaller, the caller-identification co
BMC TV expands UK network for major sports broadcasts with Adtran and Fibre Technologies Ltd15.9.2026 14:00:00 CEST | Press release
News summary: Rising capacity and performance demands for live sports are driving new requirements at the broadcast network edge Adtran’s packet edge solution enables BMC TV to reliably aggregate and distribute live feeds across its LMX Live nationwide network Scalable, deterministic architecture supports major live sports events today while providing a path to 400G services Adtran today announced that BMC TV has expanded its UK core network, harnessing Adtran technology to support coverage of major events, including the FIFA World Cup and extensive racecourse broadcasting across the UK. The new infrastructure strengthens BMC TV’s packet edge, access and aggregation layers, enabling reliable distribution of live feeds across multiple locations with deterministic, low-latency performance. Designed to scale with growing broadcast demands, the network also provides a clear route to future 400Gbit/s services. The deployment was delivered in partnership with Fibre Technologies Ltd, which le
Two Powerhouses, One Drive: SharkNinja Joins McLaren Racing as Official Partner15.9.2026 14:00:00 CEST | Press release
Global partnership includes exclusive content, fan experiences, and driver and ambassador collaborationsSharkNinja will work with the McLaren Racing Accelerator Program, drawing on McLaren’s engineering expertise to help shape future SharkNinja products SharkNinja, Inc. (NYSE: SN), a global product design and technology company, is proud to announce its new global partnership with McLaren Racing, the renowned British motorsport team, across its Formula 1, IndyCar, World Endurance Championship, and F1 Academy entries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915026788/en/ As an Official Partner, SharkNinja will become part of the McLaren Racing ecosystem through exclusive experiences, content, and activations designed to connect fans with the ethos and innovation of the two brands. Through the McLaren Racing Accelerator Program, engineers from both companies will work together to apply advanced racing methodologies t
The LYCRA Company Appoints Hua Du as Chief Executive Officer15.9.2026 14:00:00 CEST | Press release
The LYCRA Company, a global leader in developing fiber and technology solutions for the apparel and personal care industries, announced today that Hua Du has been appointed chief executive officer, effective September 14, as the company enters its next chapter following the successful completion of its financial restructuring. Du succeeds Dean Williams, who served as interim chief executive officer and will continue in his role as chief financial officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915565505/en/ The LYCRA Company Appoints Hua Du as Chief Executive Officer. With 30 years of leadership experience in the specialty chemical and biotechnology industries, Du is well positioned to lead the company into its next chapter. Du brings 30 years of leadership experience in the specialty chemical and biotech-based industries, driving transformational growth across global businesses. Du most recently served as CEO of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom